IL322931A - נוגדן אנושי נגד עמילואיד בתא 42 - Google Patents

נוגדן אנושי נגד עמילואיד בתא 42

Info

Publication number
IL322931A
IL322931A IL322931A IL32293125A IL322931A IL 322931 A IL322931 A IL 322931A IL 322931 A IL322931 A IL 322931A IL 32293125 A IL32293125 A IL 32293125A IL 322931 A IL322931 A IL 322931A
Authority
IL
Israel
Prior art keywords
antibody
sequence
seq
antigen
expression
Prior art date
Application number
IL322931A
Other languages
English (en)
Original Assignee
Alzinova Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alzinova Ab filed Critical Alzinova Ab
Publication of IL322931A publication Critical patent/IL322931A/he

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL322931A 2023-03-20 2024-03-19 נוגדן אנושי נגד עמילואיד בתא 42 IL322931A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB202304005 2023-03-20
PCT/EP2024/057283 WO2024194298A1 (en) 2023-03-20 2024-03-19 Humanised antibody against amyloid beta 42

Publications (1)

Publication Number Publication Date
IL322931A true IL322931A (he) 2025-10-01

Family

ID=90481878

Family Applications (1)

Application Number Title Priority Date Filing Date
IL322931A IL322931A (he) 2023-03-20 2024-03-19 נוגדן אנושי נגד עמילואיד בתא 42

Country Status (6)

Country Link
KR (1) KR20250158052A (he)
CN (1) CN120882742A (he)
AU (1) AU2024238598A1 (he)
IL (1) IL322931A (he)
MX (1) MX2025009326A (he)
WO (1) WO2024194298A1 (he)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2262526B1 (en) 2008-04-14 2015-12-02 Alzinova AB Stable amyloid beta monomers and oligomers
EP2497782A1 (en) 2011-03-08 2012-09-12 Alzinova AB Anti oligomer antibodies and uses thereof

Also Published As

Publication number Publication date
KR20250158052A (ko) 2025-11-05
WO2024194298A1 (en) 2024-09-26
AU2024238598A1 (en) 2025-09-18
MX2025009326A (es) 2025-10-01
CN120882742A (zh) 2025-10-31

Similar Documents

Publication Publication Date Title
JP7016217B2 (ja) 二重特異性を有するｔ細胞エンゲージ抗体コンストラクト
JP7026610B2 (ja) メソテリン及びｃｄ３に結合する二重特異性抗体構築物
CN107849136B (zh) 抗TfR抗体及其在治疗增殖性和炎性疾病中的用途
AU2018280679B2 (en) Novel anti-HSA antibodies
AU2022229993A9 (en) Pharmaceutical composition containing anti-tslp antibody
RS57827B1 (sr) Antitela koja vezuju protein 1 prepoznavanja peptidoglikana
WO2018224439A1 (en) Novel anti-hsa antibodies
JP2016027801A (ja) 改良された抗血清アルブミン結合変異体
JP2025011106A (ja) 二重特異性抗体コンストラクトの下流プロセシング
CN115427454A (zh) 针对粘蛋白17的抗体及其用途
WO2024046234A1 (zh) 抗人补体c5抗体以及其融合蛋白
KR20190067771A (ko) 인터루킨-6의 인간 수용체에 결합가능한 항체 또는 항원 결합성 단편
KR20240031229A (ko) 알파-시누클레인병증 치료용 항체
EP4255934A1 (en) Heterodimeric iga fc constructs and methods of use thereof
JP2022545925A (ja) 抗ｔｆｐｉモノクローナル抗体
WO2024225446A1 (ja) 新規なＮａｖ１．７モノクローナル抗体を含む医薬組成物
IL322931A (he) נוגדן אנושי נגד עמילואיד בתא 42
TW202325739A (zh) 新穎Nav1.7單株抗體
US20250154242A1 (en) Anti-tnf-alpha antibodies and compositions
US20240270857A1 (en) Anti-il-36r antibody and use thereof
JP2025537300A (ja) 補体阻害ハイブリッドタンパク質突然変異体および抗体とその融合タンパク質
WO2023039613A2 (en) Lilrb2-specific monoclonal antibodies and methods of their use
JP2025528101A (ja) 多重特異性ポリペプチド複合体
KR20240021859A (ko) 이중특이적 항-ccl2 항체
HK40023336B (en) Anti-hsa antibodies